MCK Stock Recent News

Drug distributor McKesson said on Monday it would buy a controlling stake in community cancer center Florida Cancer Specialists & Research Institute's business and administrative services unit, Core Ventures, for $2.49 billion in cash.

Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.

McKesson (MCK) shares tumbled Thursday, a day after the healthcare services provider warned that limited supply of GLP-1 weight-loss drugs is hurting sales.

McKesson's (MCK) first-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.2% on Thursday.

Although the revenue and EPS for McKesson (MCK) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

McKesson (MCK) came out with quarterly earnings of $7.88 per share, beating the Zacks Consensus Estimate of $7.16 per share. This compares to earnings of $7.27 per share a year ago.

McKesson Corp reported weaker-than-expected first-quarter revenue on Wednesday due to soft demand for branded and specialty drugs that dragged sales down in its U.S. pharmaceuticals segment.

So far in 2024, healthcare stocks have run into periodic earnings challenges compared to historical first quarters. For example, quarterly earnings for healthcare stocks across the board were down 25% compared to first-quarter 2023 earnings.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.